[1] Goldring C, Antoine DJ, Bonner F, et al. Stem Cell-Derived Models to Improve Mechanistic Understanding and Prediction of Human Drug-Induced Liver Injury. Hepatology, 2017, 65: 710-721.
[2] Waring MJ, Arrowsmith J, Leach AR, et al. An analysis of the attrition of drug candidates from four major pharmaceutical companies. Nat Rev Drug Discov, 2015, 14: 475-486.
[3] Baxter M, Withey S, Harrison S, et al. Phenotypic and functional analyses show stem cell-derived hepatocyte-like cells better mimic fetal rather than adult hepatocytes. J Hepatol, 2015, 62: 581-589.
[4] Ulvestad M, Nordell P, Asplund A, et al. Drug metabolizing enzyme and transporter protein profiles of hepatocytes derived from human embryonic and induced pluripotent stem cells. Biochem Pharmacol, 2013, 86: 691-702.
[5] Takayama K, Morisaki Y, Kuno S, et al. Prediction of interindividual differences in hepatic functions and drug sensitivity by using human iPS-derived hepatocytes. Proc Natl Acad Sci USA, 2014, 111: 16772-16777.
[6] Park BK, Boobis A, Clarke S, et al. Managing the challenge of chemically reactive metabolites in drug development. Nat Rev Drug Discov, 2011, 10: 292-306.
[7] Ware BR, Berger DR, Khetani SR. Prediction of drug-induced liver injury in micropatterned co-cultures containing iPSCderived human hepatocytes. Toxicol Sci, 2015, 145: 252-262.
[8] Schwanhausser B, Busse D, Li N, et al. Global quantification of mammalian gene expression control. Nature, 2011, 473: 337-342.
[9] Zinchenko YS, Schrum LW, Clemens M, et al. Hepatocyte and Kupffer cells co-cultured on micropatterned surfaces to optimize hepatocyte function. Tissue Eng, 2006, 12: 751-761.
[10] Rowe C, Gerrard DT, Jenkins R, et al. Proteome-wide analyses of human hepatocytes during differentiation and dedifferentiation. Hepatology, 2013, 58: 799-809. |
